Medtronic MiniMed, Inc.
Clinical trials sponsored by Medtronic MiniMed, Inc., explained in plain language.
Makes insulin pumps and diabetes management devices.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Implantable pump could ease diabetes management for 40 patients Results expected Dec 2026 (estimated)
- New insulin pump system put to the test in 400-Person safety trial Results expected Jan 2027 (estimated)
- New insulin pump system aims to improve diabetes management Results expected Mar 2027 (estimated)
-
New insulin pump system aims to improve diabetes management
Disease control Recruiting nowThis study will test a new experimental automated insulin delivery system (called NMX8) in 116 people with type 1 or type 2 diabetes who need insulin. The goal is to see if the new system is safe and works as well as the current Medtronic 780G system at keeping blood sugar in a h…
Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Implantable pump could ease diabetes management for 40 patients
Disease control Recruiting nowThis study is testing a new implantable insulin pump (MIIPS 2020) in 40 adults with type 1 diabetes whose blood sugar is hard to control with standard insulin shots or external pumps. The pump is placed inside the body and delivers insulin directly, aiming to reduce dangerous hig…
Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC